Attovia Therapeutics, Inc. (NASDAQ:ATTO) Stock Short Interest Report for September

Attovia Therapeutics, Inc. (NASDAQ:ATTO) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totaling 1,649,612 shares, a growth of 98.5% from the September 15th total of 831,090 shares. Currently, 3.6% of the company’s stock are sold short. Based on an average daily volume of 553,841 shares, the days-to-cover ratio is presently 3.0 days.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ATTO shares. Wall Street Zen upgraded Attovia Therapeutics to a “sell” rating in a report on Saturday, September 19th. Lifesci Capital initiated coverage on shares of Attovia Therapeutics in a research report on Monday, August 31st. They set an “outperform” rating and a $45.00 target price for the company. Zacks Research upgraded shares of Attovia Therapeutics to a “hold” rating in a report on Friday, September 4th. Citigroup started coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued a “buy” rating and a $30.00 price target on the stock. Finally, Leerink Partners initiated coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $52.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.20.

Attovia Therapeutics Stock Up 0.2%

Shares of ATTO stock traded up $0.02 during trading hours on Thursday, reaching $14.98. 390,049 shares of the company’s stock were exchanged, compared to its average volume of 354,496. Attovia Therapeutics has a fifty-two week low of $14.23 and a fifty-two week high of $28.00. The company has a market capitalization of $684.03 million and a PE ratio of -3.04. The business’s fifty day simple moving average is $20.19.

Attovia Therapeutics (NASDAQ:ATTO) last announced its quarterly earnings data on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter. The firm had revenue of $0.45 million for the quarter. Equities research analysts forecast that Attovia Therapeutics will post -4.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Attovia Therapeutics

In related news, major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the acquisition, the insider owned 6,154,213 shares in the company, valued at $104,621,621. This trade represents a 10.57% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio acquired 382,352 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,499,984.00. Following the completion of the transaction, the insider directly owned 4,181,367 shares of the company’s stock, valued at $71,083,239. This represents a 10.06% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 2,740,587 shares of company stock valued at $47,269,979 in the last 90 days. Corporate insiders own 0.99% of the company’s stock.

About Attovia Therapeutics

Attovia Therapeutics, Inc is a clinical-stage biotechnology company developing antibody-based medicines for immune-mediated and inflammatory diseases. The company uses proprietary antibody-engineering technologies to design therapies intended to modulate biological pathways involved in chronic inflammation.

Attovia’s development pipeline includes ATTO-1310, an investigational antibody therapy being advanced for atopic dermatitis and potentially other inflammatory conditions. The company’s broader research efforts focus on developing treatments that may offer targeted activity and durable effects for patients with immune-related diseases.

Attovia Therapeutics is advancing its programs through preclinical and clinical development and has not yet established a commercial product portfolio.